Roivant Sciences (ROIV) Non-Current Assets (2021 - 2026)
Roivant Sciences (ROIV) posted Non-Current Assets of $153000.0 for Q1 2026, down 100.0% on a QoQ basis from $4.3 billion in Q4 2025, and down 24.26% year-over-year from $202000.0 in Q1 2025.
Roivant Sciences (ROIV) Non-Current Assets (2021 - 2026) Analysis & Trends
Roivant Sciences' Non-Current Assets history runs 6 years deep, the most recent figure standing at $153000.0 for Q1 2026.
- Quarterly Non-Current Assets fell 24.26% year-over-year to $153000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153000.0 (down 24.26% YoY) and the FY2026 annual result came in at $153000.0, down 24.26% from the prior year.
- Non-Current Assets was $153000.0 for Q1 2026 at Roivant Sciences, down from $4.3 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $4.3 billion in Q4 2025 and bottomed at $153000.0 in Q1 2026.
- A 5-year average of $837.3 million and a median of $513.9 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets soared 257.11% — and 2025, when it plunged 98.6%.
- Roivant Sciences' Non-Current Assets stood at $556.7 million in 2022, then surged by 257.11% to $2.0 billion in 2023, then gained by 17.73% to $2.3 billion in 2024, then jumped by 83.05% to $4.3 billion in 2025, then slumped by 100.0% to $153000.0 in 2026.
- Business Quant data shows ROIV's Non-Current Assets at $153000.0 in Q1 2026, $4.3 billion in Q4 2025, and $551.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | 153,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153,000.00 |
| Dec 31, 2025 | 4.28 Bn |
| Sep 30, 2025 | 550.95 Mn |
| Jun 30, 2025 | 416.85 Mn |
| Mar 31, 2025 | 202,000.00 |
| Dec 31, 2024 | 2.34 Bn |
| Sep 30, 2024 | 404.91 Mn |
| Jun 30, 2024 | 494.95 Mn |
| Mar 31, 2024 | 14.42 Mn |
| Dec 31, 2023 | 1.99 Bn |
| Sep 30, 2023 | 513.92 Mn |
| Jun 30, 2023 | 575.49 Mn |
| Mar 31, 2023 | 591.02 Mn |
| Dec 31, 2022 | 556.73 Mn |
| Sep 30, 2022 | 500.67 Mn |
| Jun 30, 2022 | 560.96 Mn |
| Mar 31, 2022 | 438.61 Mn |
| Dec 31, 2021 | 511.84 Mn |
| Sep 30, 2021 | 547.15 Mn |
| Jun 30, 2021 | 397.09 Mn |